Dual HER2 blockade: preclinical and clinical data

Breast Cancer Research

Table 3 Published or presented multicenter neoadjuvant trials in HER2-positive disease including pertuzumab

Study	Neoadjuvant regimen	pCR breast and lymph node T (%)	pCR breast and lymph node P (%)	pCR breast and lymph node combination T + P (%)	pCR breast and lymph node combination T + P without chemotherapy (%)	Statistical significance
NeoSphere [19]	D x 4 with T and/or P	21.5	17.7	39.3	11.2	NR for pCR breast and lymph node. For pCR breast only between T + P and T, P = 0.0141
TRYPHAENA [43]	Arm A, FECPH → DPH; Arm B, FEC → DPH; Arm C, TCHP	50.7	45.3	51.9	NA	Primary endpoint was cardiac safety, P value NR

D, docetaxel; DPH, docetaxel, pertuzumab and trastuzumab; FEC, fluorouracil, epirubicin, cyclophosphamide; FECPH, fluorouracil, epirubicin, cyclophosphamide, pertuzumab and trastuzumab; HER, human epidermal growth factor receptor; NA, not applicable; NR, not reported; P, pertuzumab; pCR, pathologic complete response; T, trastuzumab; TCHP, docetaxel, carboplatin, trastuzumab and pertuzumab.

ISSN: 1465-542X